Expert oncologists discuss the current treatment landscape and latest data in the treatment of patients with AL amyloidosis with cardiac involvement.
EP. 1: AL Amyloidosis: Background, Patient Profile, and Staging
Expert oncologists Dr. Jeffrey Zonder and Dr. Shaji Kumar discuss AL amyloidosis background, typical patient profiles, and disease staging and risk stratification.
EP. 2: Navigating the Differential Diagnosis of AL Amyloidosis
Dr. Kumar discusses best practices for accurately and prompt diagnosing AL amyloidosis as well as navigating differential diagnosis.
EP. 3: Treatment Approaches in AL Amyloidosis
Dr. Zonder discusses the current treatment landscape in AL amyloidosis, highlighting recent advances.
EP. 4: Limitations of Available Treatment Options for Patients with Cardiac Involvement
Expert oncologist Dr. Kumar provides his assessment of unmet needs in AL Amyloidosis, particularly patients with cardiac involvement.
EP. 5: Birtamimab in AL Amyloidosis: Key Takeaways from the Phase III VITAL Trial
Drs. Kumar and Zonder discuss results from the Phase III Vital trial investigating birtamimab and key takeaways.
EP. 6: Birtamimab Safety Profile in the VITAL Study
Dr. Zonder discusses the safety profile of birtamimab in the VITAL study and the clinical implications.
EP. 7: Adverse Event Management in AL Amyloidosis
Dr. Kumar discusses strategies for managing adverse events in patients with AL amyloidosis.
EP. 8: Ongoing AFFIRM-AL Trial Background, Patient Eligibility, and Active Enrollment
Dr. Kumar and Dr. Zonder discuss the ongoing confirmatory Phase III AFFIRM-AL trial investigating the efficacy and safety of birtamimab and ongoing recruitment in the trial.
EP. 9: Revolutionizing the AL Amyloidosis Treatment Paradigm: Novel Agents and Combination Approaches
Expert oncologists discuss the progression treatment landscape in AL amyloidosis and agents of investigation.
EP. 10: Clinical Pearls and Future Directions in AL Amyloidosis
Dr. Zonder and Dr. Kumar share their clinical pearls and perspectives on future directions in the treatment of AL amyloidosis.
DK210 (EGFR) Induces Immune Response Without Increased CRS or Regulatory T Cells in Solid Tumors
Siglec-15 Represents Potential Therapeutic Target in NSCLC, Other Solid Tumors
Radiomic Biomarkers Predict Response in Lung and Liver Uveal Melanoma Metastases
BT7480 Shows Preliminary Activity in Nectin-4+, CD137+ Tumors